Personalis, Inc. $PSNL Shares Acquired by Aberdeen Group plc

Aberdeen Group plc lifted its holdings in shares of Personalis, Inc. (NASDAQ:PSNL) by 36.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,249,895 shares of the company’s stock after acquiring an additional 861,948 shares during the period. Aberdeen Group plc owned 3.66% of Personalis worth $25,869,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. ARK Investment Management LLC boosted its stake in shares of Personalis by 11.3% during the third quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after buying an additional 802,268 shares during the period. AIGH Capital Management LLC grew its stake in shares of Personalis by 4.5% in the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company’s stock valued at $25,376,000 after purchasing an additional 168,143 shares during the last quarter. Kennedy Capital Management LLC grew its stake in shares of Personalis by 196.2% in the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock valued at $12,617,000 after purchasing an additional 1,281,695 shares during the last quarter. Blue Water Life Science Advisors LP increased its holdings in shares of Personalis by 42.6% in the second quarter. Blue Water Life Science Advisors LP now owns 1,676,300 shares of the company’s stock valued at $10,997,000 after purchasing an additional 500,900 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Personalis by 11.0% in the third quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock valued at $7,894,000 after purchasing an additional 120,027 shares during the period. 61.91% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PSNL has been the subject of several recent research reports. Needham & Company LLC increased their price target on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, February 27th. BTIG Research boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Guggenheim raised their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Morgan Stanley lowered their target price on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, March 5th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.50.

Personalis Price Performance

Shares of PSNL opened at $6.58 on Monday. Personalis, Inc. has a 52-week low of $2.83 and a 52-week high of $11.50. The company has a 50-day simple moving average of $8.11 and a 200-day simple moving average of $8.41. The company has a market capitalization of $688.47 million, a PE ratio of -7.23 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last issued its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.05. The company had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. On average, research analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.